Clinical Trials

A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)


Study ID
ASTX030-01

NCT Number
NCT04256317 (Click on the NCT number for more information about the trial)

Research Study Number
2020-0035

Principle Investigator
Dr. McCloskey II, James K.

Phase
NA

Sponsor
Astex Pharmaceuticals


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now